On December 27th, the Wall Street Journal‘s Heath Blog published a post on MBBP client Dart Therapeutics, a company focused on developing treatment for Duchenne muscular dystrophy (DMD). Dart Therapeutics was formed by two families, the Secklers and Wickas, who each have a son diagnosed with DMD, a genetic neuromuscular disorder. They were frustrated with the lack of research and experimental drug development programs for DMD and decided to form their own company Dart Therapeutics. Set up with the purpose of “identifing potential compounds, making deals, and developing the drugs”, Dart Therapeutics created a new innovative business model, one in which the blog posting describes as a ” do-it-yourself drug development”. Ultimately, the goal of Dart is not only to help do-it-yourself drug development for Duchenne but also other orphan diseases that can use outside experts to negotiate deals, oversee experiments, and work with the FDA.
Please read the full article for more information.